Thursday was hardly a good day to be a shareholder of Intellia Therapeutics ( NTLA -20.51%). After the biotech delivered some news from the lab and witnessed one analyst's negative reaction to it, the ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regularly ...

Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

Poseida Therapeutics (PSTX) announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a ...

Researchers expand on their phase one study demonstrating a single treatment with a CRISPR-Cas9-based gene editing therapy, ...

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...